找不到产品?留下需求帮您找
一键询价UPCISCC090 人舌头鳞癌细胞 QCH766
一周
3500¥
KNS62 人肺支气管鳞状细胞癌 QCH767
一周
3500¥
HCC95 人肺腺癌细胞 QCH768
一周
3500¥
HARA 人肺腺癌细胞 QCH769
一周
3500¥
EPLC272H 人肺腺癌细胞 QCH770
一周
4000¥
NCI-H810 人非小细胞肺癌细胞 QCH771
一周
5000¥
HBL-1 人弥漫性大B细胞淋巴瘤 QCH772
一周
1800¥
FTC238 人滤泡状甲状腺癌细胞,肺转移 XY-H773
一周
3500¥
SNU-719 人胃癌细胞 QCH774
一周
3500¥
BT549+GFP+LUC 人乳腺癌细胞 QCH766GL
钦诚生物 | 一周
4500¥
公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述: 产品名称:BI 224436 产品别名:见爱必信官网 英文别名:BI 224436 靶点:HIV Integrase CAS:1155419-89-8 纯度: 外观:见爱必信官网 保存方法: 描述:BI 224436 is a novel HIV-1 noncatalytic site integrase inhibitor with EC50 values of less than 15 nM against different HIV-1 laboratory strains. 溶解性:10 mM in DMSO 体外研究: BI 224436 has cellular cytotoxicity of more than 90 μM. BI 224436 has a low, 2.1-fold decrease in antiviral potency in the presence of 50% human serum. BI 224436 retains full antiviral activity against recombinant viruses encoding INSTI resistance substitutions N155S, Q148H, and E92Q. BI 224436 displays an additive effect in combination with most approved antiretrovirals, including INSTIs. BI 224436 has drug-like in vitro absorption, distribution, metabolism, and excretion (ADME) properties, including Caco-2 cell permeability, solubility, and low cytochrome P450 inhibition. 体内研究:BI 224436 exhibits excellent pharmacokinetic profiles in rat (clearance as a percentage of hepatic flow , 0.7%; bioavailability , 54%), monkey (CL, 23%; F, 82%), and dog (CL, 8%; F, 81%).
产品信息订购:
|